Network-Based/VBN
Protein/NN
Biomarker/NN
Discovery/NN
Platforms/NNS
./.
====================
The/DT
advances/NNS
in/IN
mass/NN
spectrometry-based/VBN
proteomics/NNS
technologies/NNS
have/VBP
enabled/VBN
the/DT
generation/NN
of/IN
global/JJ
proteome/JJ
data/NNS
from/IN
tissue/NN
or/CC
body/NN
fluid/NN
samples/NNS
collected/JJ
from/IN
a/DT
broad/JJ
spectrum/NN
of/IN
human/JJ
diseases/NNS
./.
====================
Comparative/JJ
proteomic/JJ
analysis/NN
of/IN
global/JJ
proteome/JJ
data/NNS
identifies/VBZ
and/CC
prioritizes/VBZ
the/DT
proteins/NNS
showing/VBG
altered/JJ
abundances/NNS
,/,
called/VBN
differentially/RB
expressed/VBN
proteins/NNS
(/(
DEPs/NNS
)/)
,/,
in/IN
disease/NN
samples/NNS
,/,
compared/VBN
to/TO
control/VB
samples/NNS
./.
====================
Protein/NN
biomarker/NN
candidates/NNS
that/DT
can/MD
serve/VB
as/IN
indicators/NNS
of/IN
disease/NN
states/NNS
are/VBP
then/RB
selected/VBN
as/IN
key/JJ
molecules/NNS
among/IN
these/DT
proteins/NNS
./.
====================
Recently/RB
,/,
it/PRP
has/VBZ
been/VBN
addressed/VBN
that/DT
cellular/JJ
pathways/NNS
can/MD
provide/VB
better/RBR
indications/NNS
of/IN
disease/NN
states/NNS
than/IN
individual/JJ
molecules/NNS
and/CC
also/RB
network/NN
analysis/NN
of/IN
the/DT
DEPs/NNS
enables/VBZ
effective/JJ
identification/NN
of/IN
cellular/JJ
pathways/NNS
altered/JJ
in/IN
disease/NN
conditions/NNS
and/CC
key/JJ
molecules/NNS
representing/VBG
the/DT
altered/JJ
cellular/JJ
pathways/NNS
./.
====================
Accordingly/RB
,/,
a/DT
number/NN
of/IN
network-based/JJ
approaches/NNS
to/TO
identify/VB
disease-related/JJ
pathways/NNS
and/CC
representative/JJ
molecules/NNS
of/IN
such/JJ
pathways/NNS
have/VBP
been/VBN
developed/VBN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
summarize/VBP
analytical/JJ
platforms/NNS
for/IN
network-based/JJ
protein/NN
biomarker/NN
discovery/NN
and/CC
key/JJ
components/NNS
in/IN
the/DT
platforms/NNS
./.
====================
For/IN
a/DT
last/JJ
decade/NN
,/,
mass/NN
spectrometry/NN
(/(
MS/NN
)/)
-based/JJ
proteomic/JJ
technologies/NNS
have/VBP
emerged/VBN
as/IN
a/DT
core/NN
technology/NN
to/TO
measure/VB
protein/NN
expression/NN
and/CC
the/DT
sites/NNS
with/IN
post-translational/JJ
modifications/NNS
(/(
PTMs/NNS
)/)
on/IN
large/JJ
scales/NNS
./.
====================
However/RB
,/,
MS-based/JJ
proteome/JJ
analysis/NN
has/VBZ
been/VBN
possible/JJ
for/IN
only/RB
a/DT
limited/JJ
number/NN
of/IN
proteins/NNS
and/CC
also/RB
limited/JJ
in/IN
accurately/RB
detecting/VBG
low/JJ
abundant/JJ
proteins/NNS
and/CC
the/DT
peptides/NNS
with/IN
low/JJ
abundant/JJ
PTMs/NNS
[/(
1234/CD
]/)
./.
====================
Recent/JJ
advances/NNS
in/IN
high-resolution/JJ
peptide/NN
separation/NN
,/,
comprehensive/JJ
fractionation/NN
,/,
and/CC
high/JJ
performance/NN
MS/NN
considerably/RB
improved/JJ
the/DT
proteome/JJ
size/NN
and/CC
depth/NN
(/(
increased/VBN
numbers/NNS
of/IN
proteins/NNS
and/CC
PTM/NN
sites/NNS
measured/VBN
)/)
and/CC
also/RB
the/DT
accuracy/NN
in/IN
quantitative/JJ
information/NN
of/IN
proteomic/JJ
data/NNS
(/(
abundances/NNS
of/IN
proteins/NNS
and/CC
PTM/NN
sites/NNS
)/)
[/(
5/CD
]/)
./.
====================
Moreover/RB
,/,
MS-based/JJ
proteome/VBP
analysis/NN
required/VBD
large/JJ
amounts/NNS
of/IN
samples/NNS
to/TO
measure/VB
reliably/RB
proteins/NNS
and/CC
PTM/NN
sites/NNS
./.
====================
To/TO
resolve/VB
this/DT
problem/NN
,/,
the/DT
methods/NNS
for/IN
serial/JJ
enrichments/NNS
of/IN
different/JJ
PTMs/NNS
from/IN
the/DT
same/JJ
sample/NN
have/VBP
been/VBN
developed/VBN
to/TO
significantly/RB
reduce/VB
the/DT
sample/NN
amount/NN
required/VBN
[/(
6/CD
]/)
./.
====================
These/DT
advanced/JJ
MS-based/JJ
proteomic/JJ
technologies/NNS
have/VBP
facilitated/VBN
the/DT
generation/NN
of/IN
proteome/JJ
and/CC
PTM/NN
profiles/NNS
in/IN
tissue/NN
and/CC
body/NN
fluid/NN
(/(
plasma/serum/NN
,/,
urine/NN
,/,
ascites/VBZ
,/,
cerebrospinal/JJ
fluid/NN
,/,
synovial/JJ
fluid/NN
,/,
saliva/NN
,/,
and/CC
tear/JJ
)/)
samples/NNS
collected/JJ
from/IN
the/DT
patients/NNS
with/IN
a/DT
broad/JJ
spectrum/NN
of/IN
human/JJ
diseases/NNS
./.
====================
Comparative/JJ
proteomic/JJ
analysis/NN
of/IN
samples/NNS
from/IN
the/DT
patients/NNS
and/CC
healthy/JJ
control/NN
subjects/NNS
is/VBZ
commonly/RB
applied/VBN
to/TO
identify/VB
protein/NN
biomarker/NN
candidates/NNS
[/(
78910/CD
]/)
./.
====================
In/IN
this/DT
analysis/NN
,/,
proteome/DT
profiles/NNS
are/VBP
first/JJ
obtained/VBN
for/IN
tissue/NN
or/CC
body/NN
fluid/NN
samples/NNS
collected/JJ
from/IN
the/DT
patients/NNS
with/IN
a/DT
target/NN
disease/NN
and/CC
also/RB
healthy/JJ
subjects/NNS
,/,
and/CC
the/DT
proteins/NNS
showing/VBG
altered/JJ
abundances/NNS
,/,
called/VBN
differentially/RB
expressed/VBN
proteins/NNS
(/(
DEPs/NNS
)/)
,/,
in/IN
disease/NN
samples/NNS
,/,
compared/VBN
to/TO
control/JJ
samples/NNS
are/VBP
then/RB
identified/VBD
(/(
discovery/RB
phase/NN
)/)
[/(
10/CD
]/)
./.
====================
In/IN
the/DT
protein/NN
biomarker/NN
discovery/RB
platforms/NNS
,/,
about/RB
hundred/VBD
DEPs/NNS
are/VBP
selected/VBN
as/IN
an/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
,/,
and/CC
their/PRP$
altered/JJ
expression/NN
are/VBP
then/RB
verified/VBN
in/IN
a/DT
small/JJ
cohort/JJ
of/IN
the/DT
patients/NNS
,/,
which/WDT
is/VBZ
independent/JJ
to/TO
the/DT
patients/NNS
used/VBN
in/IN
the/DT
discovery/NN
phase/NN
(/(
verification/RB
phase/NN
)/)
[/(
5/CD
]/)
./.
====================
However/RB
,/,
the/DT
number/NN
of/IN
DEPs/NNS
is/VBZ
often/RB
larger/RBR
than/IN
100/CD
,/,
and/CC
how/WRB
to/TO
select/JJ
the/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
is/VBZ
not/RB
straightforward/JJ
,/,
although/IN
fold-changes/VBZ
and/or/CC
associations/NNS
of/IN
the/DT
DEPs/NNS
with/IN
pathophysiological/JJ
processes/NNS
in/IN
the/DT
target/NN
disease/NN
can/MD
be/VB
used/VBN
as/IN
the/DT
criteria/NNS
for/IN
selection/NN
of/IN
the/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
./.
====================
Next/RB
,/,
for/IN
the/DT
initial/JJ
candidates/NNS
whose/WP$
disease-related/JJ
alterations/NNS
in/IN
their/PRP$
abundances/NNS
were/VBD
confirmed/VBN
in/IN
the/DT
small/JJ
cohort/NN
during/IN
the/DT
verification/NN
phase/NN
,/,
their/PRP$
validity/NN
as/IN
biomarkers/NNS
is/VBZ
tested/VBN
in/IN
a/DT
large/JJ
cohort/JJ
of/IN
the/DT
patients/NNS
(/(
validation/NN
phase/NN
)/)
[/(
5/CD
]/)
./.
====================
Finally/RB
,/,
the/DT
biomarker/NN
candidates/NNS
whose/WP$
altered/JJ
expression/NN
was/VBD
confirmed/VBN
in/IN
the/DT
large/JJ
cohort/JJ
are/VBP
selected/VBN
as/IN
the/DT
final/JJ
set/NN
of/IN
biomarkers/NNS
./.
====================
Recently/RB
,/,
a/DT
number/NN
of/IN
studies/NNS
have/VBP
reported/VBN
that/IN
cellular/JJ
pathways/NNS
can/MD
serve/VB
as/IN
better/RBR
indicators/NNS
of/IN
disease/NN
states/NNS
than/IN
individual/JJ
molecules/NNS
[/(
11121314151617/CD
]/)
./.
====================
Pathway/NN
enrichment/JJ
analysis/NN
provides/VBZ
a/DT
list/NN
of/IN
cellular/JJ
pathways/NNS
enriched/VBN
by/IN
the/DT
DEPs/NNS
,/,
and/CC
a/DT
set/NN
of/IN
cellular/JJ
pathways/NNS
related/JJ
to/TO
pathophysiological/JJ
processes/NNS
can/MD
be/VB
then/RB
selected/VBN
as/IN
altered/JJ
cellular/JJ
pathways/NNS
in/IN
the/DT
target/NN
disease/NN
./.
====================
Next/RB
,/,
we/PRP
can/MD
focus/VB
on/IN
a/DT
subset/NN
of/IN
DEPs/NNS
that/DT
are/VBP
involved/VBN
in/IN
the/DT
selected/VBN
cellular/JJ
pathways/NNS
./.
====================
Furthermore/RB
,/,
network/NN
analysis/NN
for/IN
this/DT
subset/NN
of/IN
DEPs/NNS
enables/VBZ
effective/JJ
identification/NN
of/IN
key/JJ
molecules/NNS
that/WDT
represent/VBP
the/DT
selected/VBN
cellular/JJ
pathways/NNS
as/IN
protein/NN
biomarker/NN
candidates/NNS
./.
====================
Using/VBG
this/DT
approach/NN
,/,
an/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
can/MD
be/VB
selected/VBN
more/RBR
effectively/RB
than/IN
the/DT
conventional/JJ
criteria/NNS
,/,
such/JJ
as/IN
fold-changes/VBZ
and/CC
associations/NNS
of/IN
the/DT
DEPs/NNS
with/IN
the/DT
target/NN
disease/NN
./.
====================
Thus/RB
,/,
several/JJ
network-based/JJ
approaches/NNS
to/TO
identify/VB
disease-related/JJ
cellular/JJ
pathways/NNS
and/CC
representative/JJ
proteins/NNS
of/IN
such/JJ
pathways/NNS
have/VBP
been/VBN
developed/VBN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
summarize/VBP
bioinformatics/NNS
methods/NNS
for/IN
network-based/JJ
protein/NN
biomarker/NN
discovery/NN
and/CC
also/RB
key/JJ
components/NNS
in/IN
these/DT
network-based/JJ
methods/NNS
./.
====================
Peptide/NN
and/CC
protein/NN
identification/NN
====================
After/IN
obtaining/VBG
proteomic/JJ
data/NNS
from/IN
tissue/NN
or/CC
body/NN
fluid/NN
samples/NNS
using/VBG
liquid/JJ
chromatography–tandem/JJ
mass/NN
spectrometry/NN
(/(
LC-MS/MS/NN
)/)
analysis/NN
,/,
the/DT
tandem/JJ
mass/NN
spectrometry/NN
(/(
MS/MS/NN
)/)
spectra/RB
are/VBP
first/JJ
searched/VBD
against/IN
a/DT
protein/NN
sequence/NN
database/NN
(/(
e.g./FW
,/,
SWISS-Prot/JJ
or/CC
UniProt/JJ
)/)
to/TO
identify/VB
the/DT
peptide/NN
sequences/NNS
for/IN
individual/JJ
MS/MS/NN
spectra/NN
(/(
peptide/protein/NN
identification/NN
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
detected/VBN
proteome/VBP
size/NN
determines/NNS
the/DT
depth/NN
to/TO
understand/VB
disease-related/JJ
cellular/JJ
networks/NNS
based/VBN
on/IN
the/DT
proteome/NN
data/NNS
./.
====================
Thus/RB
,/,
a/DT
sufficient/JJ
size/NN
of/IN
the/DT
detected/VBN
proteome/VBP
is/VBZ
a/DT
prerequisite/NN
in/IN
effective/JJ
discovery/NN
of/IN
protein/NN
biomarkers/NNS
based/VBN
on/IN
disease-related/JJ
networks/NNS
./.
====================
To/TO
ensure/VB
an/DT
adequate/JJ
proteome/JJ
size/NN
,/,
accurate/VBP
identification/NN
of/IN
the/DT
peptides/NNS
for/IN
MS/MS/NN
spectra/NN
is/VBZ
important/JJ
through/IN
database/NN
search/VBP
using/VBG
the/DT
engine/NN
,/,
such/JJ
as/IN
Mascot/JJ
[/(
18/CD
]/)
,/,
SEQUEST/NN
[/(
19/CD
]/)
,/,
MS-GF+/NN
[/(
20/CD
]/)
,/,
or/CC
Paragon/NN
(/(
Table/JJ
1/CD
)/)
[/(
21/CD
]/)
./.
====================
During/IN
the/DT
database/NN
search/VBP
,/,
a/DT
score/RB
is/VBZ
assigned/VBN
by/IN
the/DT
search/NN
engine/NN
to/TO
each/DT
peptide/NN
that/DT
can/MD
be/VB
generated/VBN
from/IN
the/DT
sequence/NN
database/NN
,/,
which/WDT
reflects/VBZ
the/DT
degree/NN
of/IN
the/DT
agreement/NN
of/IN
the/DT
measured/VBN
MS/MS/NN
spectrum/NN
to/TO
the/DT
theoretical/JJ
spectrum/NN
of/IN
the/DT
peptide/NN
./.
====================
For/IN
example/NN
,/,
SEQUEST/NN
assigns/NNS
the/DT
scores/NNS
of/IN
X-corr/NN
,/,
deltaCorr/JJ
,/,
SPrank/NN
,/,
and/CC
SP/NN
value/NN
to/TO
the/DT
peptide/NN
,/,
whereas/IN
MS-GF+/NN
assigns/NNS
–log10/CD
(/(
E-value/JJ
)/)
to/TO
the/DT
peptide/NN
./.
====================
For/IN
each/DT
measured/VBN
MS/MS/NN
spectrum/NN
,/,
the/DT
peptide/NN
with/IN
the/DT
largest/JJS
score/RB
value/NN
is/VBZ
then/RB
selected/VBN
,/,
which/WDT
defines/VBZ
a/DT
peptide-spectrum/NN
match/VBP
(/(
PSM/NN
)/)
./.
====================
Next/RB
,/,
the/DT
statistical/JJ
significance/NN
of/IN
the/DT
PSMs/NNS
resulted/VBD
from/IN
the/DT
database/NN
search/VBP
is/VBZ
evaluated/VBN
using/VBG
a/DT
statistical/JJ
method/NN
,/,
such/JJ
as/IN
PeptideProphet/NN
[/(
22/CD
]/)
in/IN
the/DT
Trans-Proteomic/JJ
Pipeline/NN
[/(
23/CD
]/)
or/CC
the/DT
target-decoy/NN
method/NN
(/(
Table/JJ
1/CD
)/)
[/(
24/CD
]/)
./.
====================
For/IN
example/NN
,/,
for/IN
each/DT
PSM/NN
,/,
PeptideProphet/NN
combines/NNS
the/DT
scores/NNS
(/(
X-corr/NN
,/,
deltaCorr/JJ
,/,
SPrank/NN
,/,
and/CC
SP/NN
value/NN
)/)
to/TO
an/DT
F/NN
score/RB
,/,
and/CC
a/DT
mixture/NN
of/IN
Gaussian/JJ
and/CC
Gamma/NN
distributions/NNS
is/VBZ
fitted/VBN
to/TO
the/DT
distribution/NN
of/IN
F/NN
scores/VBZ
for/IN
all/DT
PSMs/NNS
./.
====================
Using/VBG
the/DT
mixture/NN
distribution/NN
,/,
the/DT
probability/NN
of/IN
a/DT
PSM/NN
being/VBG
true/JJ
(/(
PeptideProphet/NN
p-value/NN
)/)
is/VBZ
estimated/VBN
[/(
25/CD
]/)
./.
====================
Finally/RB
,/,
the/DT
PSMs/NNS
with/IN
PeptideProphet/NN
p-value/NN
>/JJR
0.95/CD
are/VBP
selected/VBN
as/IN
the/DT
correct/JJ
PSMs/NNS
./.
====================
In/IN
the/DT
target-decoy/NN
method/NN
,/,
a/DT
reverse/JJ
sequence/NN
database/NN
was/VBD
generated/VBN
by/IN
inversing/VBG
the/DT
reference/NN
protein/NN
sequence/NN
in/IN
the/DT
database/NN
and/CC
then/RB
included/VBD
in/IN
the/DT
database/NN
prior/JJ
to/TO
the/DT
database/NN
search/VBP
./.
====================
Using/VBG
the/DT
score/NN
values/NNS
for/IN
the/DT
PSMs/NNS
in/IN
which/WDT
the/DT
peptide/NN
sequence/NN
was/VBD
obtained/VBN
from/IN
the/DT
reverse/JJ
sequence/NN
database/NN
,/,
false/VBP
discovery/NN
rates/NNS
(/(
FDRs/NNS
)/)
for/IN
all/DT
PSMs/NNS
are/VBP
estimated/VBN
[/(
24/CD
]/)
./.
====================
Finally/RB
,/,
the/DT
PSMs/NNS
with/IN
FDR/NN
</JJR
0.01/CD
are/VBP
selected/VBN
as/IN
the/DT
correct/JJ
PSMs/NNS
./.
====================
Recent/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
best/JJS
coverage/VBP
of/IN
the/DT
detected/VBN
proteome/VBP
can/MD
be/VB
obtained/VBN
by/IN
combining/VBG
the/DT
outputs/NNS
from/IN
multiple/JJ
search/VB
engines/NNS
./.
====================
For/IN
example/NN
,/,
Compid/JJ
enables/VBZ
the/DT
integration/NN
of/IN
Paragon/NN
and/CC
Mascot/NN
(/(
Table/JJ
1/CD
)/)
[/(
24/CD
]/)
by/IN
assigning/VBG
the/DT
peptides/NNS
with/IN
higher/JJR
scores/VBZ
from/IN
the/DT
two/CD
search/VB
engines/VBZ
to/TO
the/DT
MS/MS/NN
spectra/NN
,/,
which/WDT
can/MD
leads/VBZ
to/TO
unreliable/JJ
false/VBP
positive/JJ
rates/NNS
./.
====================
Also/RB
,/,
MSblender/NN
integrates/VBZ
the/DT
search/NN
scores/VBZ
from/IN
the/DT
search/NN
engines/NNS
into/IN
a/DT
probability/NN
score/RB
for/IN
every/RB
possible/JJ
PSM/NN
and/CC
then/RB
estimates/VBZ
FDRs/NNS
for/IN
the/DT
PSMs/NNS
in/IN
a/DT
reliable/JJ
manner/NN
[/(
26/CD
]/)
./.
====================
This/DT
method/NN
identifies/VBZ
more/RBR
PSMs/NNS
than/IN
any/DT
single/JJ
search/NN
engine/NN
at/IN
the/DT
same/JJ
FDR/NN
./.
====================
After/IN
identifying/VBG
all/DT
the/DT
PSMs/NNS
from/IN
the/DT
database/NN
search/VBP
,/,
a/DT
list/NN
of/IN
the/DT
detected/VBN
proteins/NNS
are/VBP
further/RBR
identified/VBN
./.
====================
Using/VBG
the/DT
SEQUEST/NN
search/VBP
outputs/NNS
,/,
the/DT
probability/NN
that/IN
a/DT
protein/NN
is/VBZ
correctly/RB
identified/VBD
(/(
ProteinProphet/NNP
p-value/JJ
)/)
is/VBZ
calculated/VBN
by/IN
statistically/RB
combining/VBG
the/DT
PeptideProphet/NN
p-values/NNS
of/IN
the/DT
peptides/NNS
derived/VBN
from/IN
the/DT
protein/NN
,/,
and/CC
the/DT
proteins/NNS
with/IN
PeptideProphet/NN
p-value/JJ
>/JJR
0.99/CD
are/VBP
selected/VBN
as/IN
the/DT
proteins/NNS
correctly/RB
identified/VBD
[/(
22/CD
]/)
./.
====================
In/IN
the/DT
target/NN
decoy/VBP
method/NN
,/,
the/DT
proteins/NNS
with/IN
more/RBR
than/IN
two/CD
non-redundant/JJ
peptides/NNS
with/IN
FDR/NN
</JJR
0.01/CD
can/MD
be/VB
considered/VBN
as/IN
the/DT
reliable/JJ
proteins/NNS
[/(
27/CD
]/)
./.
====================
Protein/NN
quantitation/NN
====================
Several/JJ
LC-MS/MS/NN
approaches/NNS
provide/VBP
quantitative/JJ
information/NN
of/IN
the/DT
peptides/NNS
identified/VBD
from/IN
the/DT
database/NN
search/VBP
(/(
protein/NN
quantification/NN
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
First/RB
,/,
prior/RB
to/TO
LC-MS/MS/NN
analysis/NN
,/,
the/DT
peptides/NNS
can/MD
be/VB
labeled/VBN
using/VBG
the/DT
isotopic/JJ
agents/NNS
,/,
such/JJ
as/IN
isotope-coded/VBN
affinity/NN
tag/NN
(/(
iCAT/JJ
)/)
[/(
28/CD
]/)
,/,
isobaric/JJ
tag/NN
for/IN
relative/JJ
and/CC
absolute/JJ
quantitation/NN
(/(
iTRAQ/LS
)/)
[/(
29/CD
]/)
,/,
or/CC
tandem/JJ
mass/NN
tags/NNS
(/(
TMT/NN
)/)
[/(
30/CD
]/)
./.
====================
For/IN
the/DT
iCAT/JJ
data/NNS
,/,
the/DT
abundance/NN
of/IN
an/DT
identified/VBN
peptide/NN
is/VBZ
estimated/VBN
as/IN
the/DT
area/NN
under/IN
the/DT
elusion/NN
curve/NN
of/IN
the/DT
peptide/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
for/IN
the/DT
iTRAQ/NN
or/CC
TMT/NN
data/NNS
,/,
the/DT
peptide/NN
abundance/NN
is/VBZ
estimated/VBN
as/IN
the/DT
intensities/NNS
of/IN
the/DT
reporter/NN
ions/NNS
in/IN
the/DT
MS/MS/NN
data/NNS
[/(
31/CD
]/)
./.
====================
Second/RB
,/,
when/WRB
no/DT
isotope/NN
labeling/NN
was/VBD
done/VBN
,/,
called/VBN
label-free/JJ
LC-MS/MS/NN
analysis/NN
,/,
the/DT
peptide/NN
abundance/NN
is/VBZ
estimated/VBN
as/IN
the/DT
area/NN
under/IN
the/DT
elusion/NN
curve/JJ
of/IN
the/DT
peptide/NN
as/IN
done/VBN
for/IN
the/DT
iCAT/JJ
data/NNS
./.
====================
Next/RB
,/,
the/DT
relative/JJ
abundance/NN
of/IN
an/DT
identified/VBN
peptide/NN
is/VBZ
calculated/VBN
as/IN
the/DT
ratio/NN
of/IN
the/DT
peptide/NN
abundances/VBZ
between/IN
patient/NN
and/CC
control/NN
samples/NNS
./.
====================
From/IN
the/DT
iCAT/JJ
data/NNS
,/,
the/DT
ratios/NNS
of/IN
the/DT
heavy/JJ
and/CC
light/JJ
peptides/NNS
are/VBP
calculated/VBN
as/IN
the/DT
relative/JJ
peptide/NN
abundance/NN
./.
====================
To/TO
estimate/VB
the/DT
relative/JJ
abundances/NNS
of/IN
a/DT
protein/NN
,/,
a/DT
list/NN
of/IN
the/DT
peptides/NNS
derived/VBN
from/IN
the/DT
proteins/NNS
are/VBP
identified/VBN
and/CC
the/DT
relative/JJ
abundances/NNS
of/IN
these/DT
peptides/NNS
are/VBP
then/RB
combined/VBN
using/VBG
a/DT
method/NN
for/IN
protein/NN
quantitation/NN
,/,
such/JJ
as/IN
the/DT
quantification/NN
tool/NN
in/IN
MaxQuant/JJ
software/RB
[/(
32/CD
]/)
or/CC
a/DT
linear/JJ
programming/VBG
method/NN
[/(
33/CD
]/)
./.
====================
Identification/NN
of/IN
differentially/RB
expressed/VBN
proteins/NNS
====================
The/DT
biomarkers/NNS
should/MD
reflect/VB
the/DT
alteration/NN
of/IN
disease-related/JJ
pathophysiological/JJ
processes/NNS
in/IN
the/DT
patient/NN
samples/NNS
,/,
compared/VBN
to/TO
controls/NNS
./.
====================
Thus/RB
,/,
the/DT
DEPs/NNS
between/IN
control/NN
and/CC
patient/NN
samples/NNS
are/VBP
identified/VBN
as/IN
the/DT
biomarker/NN
candidates/NNS
(/(
identification/NN
of/IN
DEPs/NNS
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
A/DT
number/NN
of/IN
statistical/JJ
methods/NNS
have/VBP
been/VBN
developed/VBN
for/IN
identification/NN
of/IN
the/DT
DEPs/NNS
,/,
such/JJ
as/IN
t-test/RB
[/(
34/CD
]/)
or/CC
integrative/JJ
statistical/JJ
methods/NNS
[/(
3536/CD
]/)
,/,
with/IN
the/DT
multiple/JJ
comparison/NN
correction/NN
./.
====================
These/DT
methods/NNS
compare/VBP
the/DT
relative/JJ
protein/NN
abundances/VBZ
between/IN
control/NN
and/CC
patient/NN
samples/NNS
and/CC
then/RB
estimate/VBP
the/DT
significance/NN
(/(
p-value/JJ
or/CC
FDR/NN
)/)
of/IN
the/DT
difference/NN
in/IN
the/DT
relative/JJ
protein/NN
abundances/VBZ
between/IN
control/NN
and/CC
patient/NN
samples/NNS
methods/NNS
./.
====================
The/DT
proteins/NNS
with/IN
p-value/JJ
or/CC
FDR/NN
</JJR
0.01/CD
or/CC
0.05/CD
are/VBP
then/RB
selected/VBN
as/IN
the/DT
DEPs/NNS
./.
====================
Furthermore/RB
,/,
additional/JJ
constraints/NNS
are/VBP
used/VBN
to/TO
select/VB
more/RBR
reliable/JJ
DEPs/NNS
./.
====================
For/IN
example/NN
,/,
for/IN
each/DT
DEP/NN
,/,
the/DT
number/NN
of/IN
the/DT
patients/NNS
showing/VBG
the/DT
fold-changes/NNS
larger/RBR
than/IN
a/DT
cutoff/JJ
(/(
1.5-/CD
or/CC
2-fold/JJ
)/)
is/VBZ
counted/VBN
,/,
and/CC
a/DT
subset/NN
of/IN
DEPs/NNS
with/IN
the/DT
number/NN
of/IN
patients/NNS
larger/RBR
than/IN
a/DT
certain/JJ
percentage/NN
(/(
50/CD
%/NN
of/IN
the/DT
patients/NNS
)/)
can/MD
be/VB
selected/VBN
as/IN
the/DT
reliable/JJ
DEPs/NNS
[/(
37/CD
]/)
./.
====================
Using/VBG
this/DT
criterion/NN
,/,
we/PRP
can/MD
focus/VB
on/IN
the/DT
DEPs/NNS
that/DT
are/VBP
likely/JJ
to/TO
show/VB
their/PRP$
alterations/NNS
in/IN
the/DT
abundance/NN
in/IN
at/IN
least/JJS
more/RBR
than/IN
half/DT
of/IN
the/DT
patients/NNS
when/WRB
they/PRP
were/VBD
used/VBN
as/IN
biomarker/NN
candidates/NNS
for/IN
newly/RB
collected/JJ
patient/NN
samples/NNS
./.
====================
Functional/JJ
enrichment/JJ
analysis/NN
====================
The/DT
alterations/NNS
in/IN
protein/NN
abundances/VBZ
under/IN
disease/NN
conditions/NNS
reflect/VBP
simple/JJ
clinical/JJ
symptoms/NNS
that/DT
are/VBP
commonly/RB
observed/VBN
in/IN
many/JJ
other/JJ
diseases/NNS
,/,
such/JJ
as/IN
inflammation/NN
or/CC
immune/JJ
responses/NNS
,/,
or/CC
the/DT
alterations/NNS
of/IN
the/DT
pathophysiological/JJ
processes/NNS
specific/JJ
to/TO
the/DT
target/NN
disease/NN
,/,
such/JJ
as/IN
aggregation/NN
of/IN
toxic/JJ
proteins/NNS
in/IN
neurodegenerative/JJ
diseases/NNS
./.
====================
Thus/RB
,/,
the/DT
DEPs/NNS
that/DT
are/VBP
involved/VBN
in/IN
the/DT
disease-related/JJ
pathophysiological/JJ
processes/NNS
can/MD
represent/VB
more/RBR
effectively/RB
the/DT
alterations/NNS
specific/JJ
to/TO
the/DT
target/NN
disease/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
To/TO
effectively/RB
understand/VB
the/DT
pathophysiological/JJ
processes/NNS
altered/JJ
under/IN
disease/NN
conditions/NNS
,/,
functional/JJ
enrichment/JJ
analysis/NN
is/VBZ
often/RB
performed/VBN
for/IN
the/DT
DEPs/NNS
using/VBG
diverse/JJ
enrichment/JJ
tools/NNS
./.
====================
For/IN
example/NN
,/,
the/DT
enrichment/JJ
analysis/NN
of/IN
gene/NN
ontology/RB
biological/JJ
processes/NNS
(/(
GOBPs/NNS
)/)
or/CC
Kyoto/JJ
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
(/(
KEGG/NN
)/)
pathways/NNS
can/MD
be/VB
applied/VBN
to/TO
the/DT
DEPs/NNS
using/VBG
DAVID/NN
[/(
38/CD
]/)
and/CC
PANTHER/NN
[/(
39/CD
]/)
,/,
and/CC
commercial/JJ
tools/NNS
,/,
such/JJ
as/IN
MetaCore/RB
[/(
40/CD
]/)
and/CC
Ingenuity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
,/,
QIAGEN/NN
Redwood/NN
City/NN
,/,
http/RB
:/:
//www.qiagen.com/ingenuity/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
A/DT
list/NN
of/IN
GOBPs/NNS
or/CC
KEGG/NN
pathways/NNS
with/IN
enrichment/JJ
p-value/NN
</JJR
0.05/CD
are/VBP
selected/VBN
as/IN
the/DT
pathophysiological/JJ
processes/NNS
or/CC
cellular/JJ
pathways/NNS
altered/JJ
under/IN
disease/NN
conditions/NNS
./.
====================
Of/IN
these/DT
selected/VBN
GOBPs/NNS
and/CC
KEGG/NN
pathways/NNS
,/,
a/DT
subset/NN
of/IN
the/DT
GOBPs/NNS
related/JJ
to/TO
the/DT
target/NN
disease/NN
is/VBZ
further/RBR
selected/VBN
based/VBN
on/IN
the/DT
knowledge/NN
of/IN
the/DT
target/NN
disease/NN
./.
====================
Finally/RB
,/,
a/DT
subset/NN
of/IN
the/DT
DEPs/NNS
that/DT
are/VBP
involved/VBN
in/IN
the/DT
selected/VBN
GOBPs/NNS
or/CC
KEGG/NN
pathways/NNS
related/JJ
to/TO
the/DT
target/NN
disease/NN
can/MD
be/VB
selected/VBN
as/IN
an/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
,/,
considering/VBG
that/DT
these/DT
DEPs/NNS
are/VBP
likely/JJ
to/TO
be/VB
specifically/RB
associated/VBN
with/IN
the/DT
target/NN
disease/NN
./.
====================
No/DT
enrichment/JJ
analysis/NN
mentioned/VBD
above/JJ
consider/VBP
quantitatively/RB
the/DT
differences/NNS
in/IN
fold-changes/NNS
of/IN
the/DT
DEPs/NNS
,/,
but/CC
consider/VBP
equivalently/RB
the/DT
DEPs/NNS
that/DT
were/VBD
selected/VBN
using/VBG
a/DT
fixed/JJ
cutoff/JJ
(/(
p-value/NN
and/or/CC
fold-changes/VBZ
)/)
./.
====================
To/TO
remedy/VB
this/DT
problem/NN
,/,
several/JJ
functional/JJ
class/NN
scoring/VBG
methods/NNS
have/VBP
been/VBN
developed/VBN
,/,
such/JJ
as/IN
gene/NN
set/NN
enrichment/JJ
analysis/NN
(/(
GSEA/NN
)/)
(/(
Table/JJ
1/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
[/(
41/CD
]/)
./.
====================
In/IN
the/DT
GSEA/NN
,/,
all/DT
D-changes/NNS
,/,
and/CC
the/DT
enrichment/JJ
of/IN
functional/JJ
modules/NNS
defined/VBN
in/IN
the/DT
database/NN
,/,
such/JJ
as/IN
the/DT
molecular/JJ
signatures/NNS
database/NN
(/(
MSigDB/NN
)/)
(/(
Table/JJ
1/CD
)/)
,/,
by/IN
the/DT
top/NN
or/CC
bottom/CC
of/IN
the/DT
ranked/JJ
protein/NN
list/NN
is/VBZ
statistically/RB
evaluated/VBD
./.
====================
Several/JJ
alternative/JJ
module-level/NN
statistics/NNS
to/TO
the/DT
conventional/JJ
GSEA/NN
have/VBP
been/VBN
also/RB
used/VBN
,/,
including/VBG
Kolmogorov-Smirnov/NN
statistic/JJ
and/CC
the/DT
maxmean/JJ
statistic/JJ
[/(
42/CD
]/)
./.
====================
Moreover/RB
,/,
as/IN
an/DT
alternative/JJ
enrichment/JJ
analysis/NN
,/,
several/JJ
pathway/NN
topology/NN
approaches/NNS
have/VBP
been/VBN
developed/VBN
,/,
such/JJ
as/IN
signaling/NN
pathway/NN
impact/VBP
analysis/NN
(/(
SPIA/NN
)/)
[/(
43/CD
]/)
and/CC
network/NN
perturbation/NN
amplitude/VBP
(/(
NPA/NN
)/)
(/(
Table/JJ
1/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
[/(
26/CD
]/)
./.
====================
These/DT
approaches/NNS
consider/VBP
whether/IN
the/DT
proteins/NNS
involved/VBN
in/IN
functional/JJ
modules/NNS
defined/VBN
by/IN
GOBP/NN
or/CC
GSEA/NN
database/NN
(/(
MSigDB/NN
)/)
interact/VBP
with/IN
each/DT
other/JJ
in/FW
cellular/JJ
networks/NNS
./.
====================
In/IN
the/DT
SPIA/NN
,/,
a/DT
conventional/JJ
overrepresentation/NN
measure/VB
,/,
as/IN
in/IN
GOBP/NN
enrichment/JJ
analysis/NN
and/CC
a/DT
topology/NN
measure/VB
of/IN
the/DT
pathway/NN
are/VBP
combined/VBN
to/TO
identify/VB
functional/JJ
modules/NNS
in/IN
which/WDT
the/DT
DEPs/NNS
are/VBP
significantly/RB
connected/VBN
./.
====================
In/IN
the/DT
NPA/NN
,/,
the/DT
upper/FW
and/CC
lower/JJR
tiers/NNS
are/VBP
defined/VBN
as/IN
cellular/JJ
pathways/NNS
(/(
e.g./FW
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
pathway/NN
activation/NN
)/)
and/CC
target/NN
genes/proteins/NNS
regulated/VBN
by/IN
the/DT
pathways/NNS
in/IN
the/DT
upper/FW
tier/RBR
,/,
respectively/RB
,/,
and/CC
positive/JJ
and/CC
negative/JJ
causal/JJ
relationships/NNS
are/VBP
defined/VBN
by/IN
the/DT
links/NNS
between/IN
the/DT
upper/FW
and/CC
lower/JJR
tiers/NNS
./.
====================
Then/RB
,/,
NPA/NN
evaluates/VBZ
the/DT
causal/JJ
relationships/NNS
by/IN
quantitatively/RB
summarizing/VBG
whether/IN
the/DT
expression/NN
changes/NNS
of/IN
the/DT
downstream/JJ
nodes/NNS
are/VBP
consistent/JJ
with/IN
pathway/NN
activation/NN
,/,
inactivation/NN
,/,
or/CC
no/DT
change/NN
./.
====================
These/DT
analyses/NNS
provide/VBP
a/DT
list/NN
of/IN
functional/JJ
modules/NNS
significantly/RB
altered/JJ
under/IN
disease/NN
conditions/NNS
./.
====================
Similar/JJ
to/TO
the/DT
case/NN
of/IN
the/DT
GOBP/NN
enrichment/JJ
analysis/NN
,/,
a/DT
subset/NN
of/IN
function/NN
modules/NNS
related/JJ
to/TO
the/DT
target/NN
disease/NN
can/MD
be/VB
identified/VBN
,/,
and/CC
a/DT
subset/NN
of/IN
DEPs/NNS
involved/VBN
in/IN
the/DT
identified/VBN
functional/JJ
modules/NNS
can/MD
be/VB
selected/VBN
as/IN
an/DT
initial/JJ
set/NN
of/IN
biomarker/NN
candidates/NNS
./.
====================
Network/NN
modeling/VBG
and/CC
analysis/NN
====================
Functional/JJ
molecules/NNS
or/CC
cellular/JJ
networks/NNS
altered/JJ
under/IN
disease/NN
conditions/NNS
interact/VBP
closely/RB
with/IN
each/DT
other/JJ
to/TO
form/VB
a/DT
disease-perturbed/JJ
cellular/JJ
network/NN
./.
====================
The/DT
network/NN
model/NN
enables/VBZ
identification/NN
of/IN
hub-like/JJ
molecules/NNS
that/WDT
can/MD
serve/VB
as/IN
core/NN
indicators/NNS
of/IN
the/DT
activities/NNS
of/IN
cellular/JJ
processes/NNS
described/VBN
in/IN
the/DT
network/NN
model/NN
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
understand/VB
the/DT
disease-perturbed/JJ
cellular/JJ
network/NN
to/TO
identify/VB
the/DT
core/NN
indicators/NNS
as/IN
the/DT
biomarker/NN
candidates/NNS
./.
====================
The/DT
core/NN
molecules/NNS
and/CC
their/PRP$
associated/VBN
cellular/JJ
pathways/NNS
have/VBP
been/VBN
further/RBR
suggested/VBD
as/IN
therapeutic/JJ
targets/NNS
or/CC
the/DT
biomarker/NN
candidates/NNS
that/DT
can/MD
be/VB
used/VBN
to/TO
evaluate/VB
the/DT
efficacy/NN
of/IN
the/DT
treatments/NNS
(/(
e.g./FW
,/,
drug/NN
efficacy/NN
)/)
for/IN
the/DT
target/NN
disease/NN
./.
====================
Hence/RB
,/,
the/DT
network-based/JJ
approaches/NNS
have/VBP
been/VBN
employed/VBN
for/IN
protein/NN
biomarker/NN
discovery/NN
./.
====================
The/DT
network-based/JJ
approaches/NNS
first/JJ
reconstruct/NN
a/DT
disease-perturbed/JJ
cellular/JJ
network/NN
model/NN
describing/VBG
the/DT
interactions/NNS
of/IN
the/DT
DEPs/NNS
or/CC
a/DT
subset/NN
of/IN
the/DT
DEPs/NNS
involved/VBN
in/IN
the/DT
selected/VBN
GOBPs/NNS
related/JJ
to/TO
the/DT
target/NN
disease/NN
using/VBG
protein-protein/JJ
(/(
PPIs/NNS
)/)
,/,
protein-DNA/JJ
(/(
PDIs/NNS
)/)
,/,
and/or/CC
protein-metabolite/JJ
interactions/NNS
(/(
PMIs/NNS
)/)
in/IN
the/DT
following/VBG
interactome/JJ
databases/NNS
(/(
Table/JJ
1/CD
,/,
Fig/NN
./.
====================
2/LS
)/)
:/:
(/(
1/LS
)/)
PPI/RB
databases/NNS
:/:
human/JJ
protein/NN
reference/RB
database/RB
(/(
HPRD/NNP
)/)
[/(
44/CD
]/)
,/,
biological/JJ
general/JJ
repository/JJ
for/IN
interaction/NN
datasets/NNS
(/(
BioGRID/NNP
)/)
[/(
45/CD
]/)
,/,
biomolecular/JJ
interaction/NN
network/NN
database/RB
(/(
BIND/NNP
)/)
[/(
46/CD
]/)
,/,
search/RB
tool/RB
for/IN
recurring/VBG
instances/NNS
of/IN
neighbouring/VBG
genes/NNS
(/(
STRING/NNP
)/)
[/(
47/CD
]/)
,/,
and/CC
Molecular/JJ
INTeraction/NN
database/RB
(/(
MINT/NNP
)/)
[/(
48/CD
]/)
;/:
(/(
2/LS
)/)
PDI/NNP
databases/NNS
:/:
EdgeExpressDB/NNP
(/(
FANTOM4-EEDB/NNP
)/)
[/(
49/CD
]/)
,/,
transcriptional/JJ
regulatory/JJ
element/NN
database/RB
(/(
TRED/NNP
)/)
[/(
50/CD
]/)
,/,
MSigDB/NNP
[/(
41/CD
]/)
,/,
MultiNet/JJ
[/(
51/CD
]/)
,/,
and/CC
MetaCore/RB
[/(
40/CD
]/)
;/:
and/CC
(/(
3/LS
)/)
PMI/NN
database/RB
:/:
KEGG/NNP
pathway/NN
database/RB
[/(
52/CD
]/)
./.
====================
Next/RB
,/,
the/DT
network/NN
model/NN
are/VBP
analyzed/VBN
to/TO
identify/VB
network/NN
modules/NNS
or/CC
clusters/NNS
each/DT
of/IN
which/WDT
includes/VBZ
a/DT
set/NN
of/IN
the/DT
nodes/NNS
densely/RB
connected/JJ
in/IN
the/DT
network/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
For/IN
network/NN
clustering/NN
or/CC
modularization/NN
,/,
a/DT
number/NN
of/IN
methods/NNS
,/,
such/JJ
as/IN
jActiveModules/NNS
[/(
53/CD
]/)
,/,
ResponseNet/NNP
[/(
54/CD
]/)
,/,
NetWalker/NNP
[/(
55/CD
]/)
,/,
and/CC
clusterMaker/NN
[/(
56/CD
]/)
,/,
have/VBP
been/VBN
developed/VBN
(/(
Table/JJ
1/CD
)/)
./.
====================
These/DT
methods/NNS
can/MD
be/VB
categorized/VBN
into/IN
two/CD
groups/NNS
./.
====================
One/CD
group/NN
,/,
such/JJ
as/IN
clusterMaker/NN
,/,
searches/VBZ
for/IN
the/DT
node/NN
clusters/NNS
based/VBN
on/IN
the/DT
network/NN
topology/NN
information/NN
such/JJ
that/IN
the/DT
nodes/NNS
in/IN
the/DT
same/JJ
cluster/NN
have/VBP
dense/JJ
connections/NNS
,/,
but/CC
sparse/JJ
connections/NNS
between/IN
the/DT
different/JJ
clusters/NNS
[/(
56/CD
]/)
./.
====================
The/DT
other/JJ
group/NN
,/,
such/JJ
as/IN
jActiveModules/NNS
,/,
uses/VBZ
the/DT
quantitative/JJ
fold-changes/NNS
of/IN
the/DT
nodes/NNS
between/IN
control/NN
and/CC
patient/NN
samples/NNS
measured/VBN
by/IN
LC-MS/MS/NN
together/RB
with/IN
the/DT
network/NN
topology/NN
information/NN
./.
====================
In/IN
this/DT
group/NN
,/,
the/DT
node/NN
clusters/NNS
are/VBP
identified/VBN
such/JJ
that/IN
the/DT
nodes/NNS
in/IN
the/DT
same/JJ
clusters/NNS
are/VBP
densely/RB
connected/JJ
and/CC
also/RB
show/VBP
similar/JJ
alteration/NN
patterns/NNS
in/IN
protein/NN
abundance/NN
[/(
53/CD
]/)
./.
====================
For/IN
functional/JJ
interpretation/NN
of/IN
the/DT
node/NN
clusters/NNS
resulted/VBD
from/IN
network/NN
clustering/NN
,/,
functional/JJ
enrichment/JJ
analyses/NNS
mentioned/VBD
above/JJ
are/VBP
then/RB
performed/VBN
for/IN
the/DT
nodes/NNS
in/IN
each/DT
network/NN
cluster/NN
./.
====================
Of/IN
the/DT
node/NN
clusters/NNS
,/,
prior/JJ
to/TO
the/DT
enrichment/JJ
analysis/NN
,/,
we/PRP
can/MD
focus/VB
on/IN
the/DT
major/JJ
network/NN
clusters/NNS
including/VBG
large/JJ
numbers/NNS
of/IN
the/DT
DEPs/NNS
./.
====================
The/DT
functional/JJ
enrichment/JJ
analysis/NN
then/RB
provide/VBP
a/DT
subset/NN
of/IN
the/DT
major/JJ
network/NN
clusters/NNS
whose/WP$
functions/NNS
(/(
e.g./FW
,/,
GOBPs/NNS
or/CC
KEGG/NN
pathways/NNS
)/)
are/VBP
associated/VBN
with/IN
the/DT
disease-related/JJ
cellular/JJ
processes/NNS
./.
====================
This/DT
subset/NN
can/MD
be/VB
considered/VBN
as/IN
potential/JJ
determinants/NNS
of/IN
the/DT
disease-perturbed/JJ
cellular/JJ
network/NN
./.
====================
Finally/RB
,/,
the/DT
hub-like/JJ
DEP/NN
in/IN
each/DT
major/JJ
network/NN
cluster/NN
is/VBZ
selected/VBN
as/IN
a/DT
biomarker/NN
candidate/NN
that/DT
can/MD
reflect/VB
the/DT
perturbation/NN
of/IN
the/DT
disease-related/JJ
cellular/JJ
process/NN
associated/VBN
with/IN
the/DT
network/NN
cluster/NN
./.
====================
Mitra/NN
et/FW
al/JJ
./.
====================
[/(
57/CD
]/)
demonstrated/VBD
the/DT
power/NN
of/IN
the/DT
network-based/JJ
biomarker/NN
discovery/NN
approach/NN
in/IN
prediction/NN
of/IN
metastatic/JJ
cancers/NNS
in/IN
human/JJ
breast/NN
cancer/NN
./.
====================
They/PRP
identified/VBD
network/NN
clusters/NNS
with/IN
dysregulated/VBN
expression/NN
using/VBG
SigArSearch/NN
and/CC
showed/VBD
that/IN
the/DT
network/NN
clusters/NNS
were/VBD
more/RBR
accurate/JJ
in/IN
distinguishing/VBG
metastatic/JJ
cancers/NNS
from/IN
non-metastatic/JJ
cancers/NNS
,/,
compared/VBN
with/IN
individual/JJ
cancer-gene/NN
markers/NNS
./.
====================
Integrative/JJ
analysis/NN
of/IN
proteomic/JJ
data/NNS
with/IN
other/JJ
global/JJ
data/NNS
====================
Other/JJ
global/JJ
data/NNS
than/IN
proteomic/JJ
data/NNS
,/,
such/JJ
as/IN
mRNA/NN
expression/NN
,/,
mutation/NN
,/,
DNA/NN
methylation/NN
,/,
histone/NN
modification/NN
,/,
can/MD
provide/VB
complementary/JJ
information/NN
that/IN
enables/VBZ
to/TO
select/VB
reliable/JJ
biomarker/NN
candidates/NNS
when/WRB
they/PRP
are/VBP
integrated/VBN
with/IN
the/DT
proteomic/JJ
data/NNS
./.
====================
The/DT
integrative/JJ
analysis/NN
of/IN
proteomic/JJ
data/NNS
with/IN
other/JJ
types/NNS
of/IN
global/JJ
datasets/NNS
can/MD
be/VB
categorized/VBN
into/IN
two/CD
groups/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
:/:
(/(
1/CD
)/)
the/DT
molecular/JJ
level/NN
and/CC
(/(
2/CD
)/)
the/DT
network-level/JJ
integration/NN
methods/NNS
[/(
58/CD
]/)
./.
====================
The/DT
proteome/JJ
data/NNS
are/VBP
contaminated/VBN
with/IN
the/DT
noises/NNS
coming/VBG
from/IN
numerous/JJ
sources/NNS
of/IN
technical/JJ
variability/NN
during/IN
LC-MS/MS/NN
experiments/NNS
and/CC
biological/JJ
variability/NN
in/IN
patient/NN
samples/NNS
during/IN
sample/NN
collection/NN
and/CC
preparation/NN
[/(
5960/CD
]/)
./.
====================
The/DT
integration/NN
of/IN
disparate/JJ
global/JJ
datasets/NNS
reduces/VBZ
the/DT
artifacts/NNS
of/IN
the/DT
noises/NNS
in/IN
selection/NN
of/IN
the/DT
DEPs/NNS
by/IN
enabling/VBG
us/PRP
to/TO
focus/VB
on/IN
the/DT
reliable/JJ
DEPs/NNS
showing/VBG
consistent/JJ
changes/NNS
between/IN
control/NN
and/CC
patient/NN
samples/NNS
in/IN
multiple/JJ
types/NNS
of/IN
global/JJ
data/NNS
[/(
58/CD
]/)
./.
====================
In/IN
the/DT
molecular/JJ
level/NN
integration/NN
method/NN
,/,
the/DT
DEPs/NNS
that/DT
show/VBP
consistent/JJ
alterations/NNS
in/IN
the/DT
other/JJ
global/JJ
datasets/NNS
(/(
e.g./FW
,/,
mRNA/NN
expression/NN
data/NNS
)/)
are/VBP
searched/VBN
,/,
assuming/VBG
that/DT
they/PRP
are/VBP
more/RBR
reliable/JJ
indicators/NNS
of/IN
the/DT
perturbation/NN
of/IN
cellular/JJ
processes/NNS
under/IN
disease/NN
conditions/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Biomarker/NN
candidates/NNS
can/MD
be/VB
then/RB
selected/VBN
from/IN
these/DT
reliable/JJ
DEPs/NNS
./.
====================
For/IN
example/NN
,/,
the/DT
DEPs/NNS
selected/VBN
from/IN
the/DT
tissue/NN
data/NNS
can/MD
be/VB
supported/VBN
by/IN
the/DT
consistency/NN
in/IN
the/DT
altered/JJ
expression/NN
of/IN
their/PRP$
corresponding/JJ
mRNAs/NNS
./.
====================
Also/RB
,/,
the/DT
DEPs/NNS
can/MD
be/VB
further/RBR
supported/VBD
by/IN
the/DT
consistency/NN
in/IN
the/DT
changes/NNS
of/IN
copy/NN
number/NN
variations/NNS
or/CC
DNA/NN
and/or/CC
histone/NN
methylations/NNS
of/IN
the/DT
corresponding/JJ
genes/NNS
./.
====================
Moreover/RB
,/,
the/DT
reliability/NN
of/IN
the/DT
DEPs/NNS
selected/VBN
from/IN
the/DT
serum/NN
proteome/VBP
data/NNS
can/MD
be/VB
supported/VBN
by/IN
the/DT
altered/JJ
expression/NN
of/IN
their/PRP$
corresponding/JJ
mRNAs/NNS
or/CC
proteins/NNS
in/IN
the/DT
tissues/NNS
from/IN
the/DT
target/NN
organ/NN
./.
====================
Hyung/NN
et/FW
al/JJ
./.
====================
[/(
61/CD
]/)
demonstrated/VBD
the/DT
value/NN
of/IN
the/DT
integrative/JJ
analysis/NN
of/IN
serum/NN
proteome/VBP
data/NNS
with/IN
mRNA/NN
expression/NN
and/CC
proteome/VBP
data/NNS
obtained/VBN
from/IN
the/DT
tissues/NNS
in/IN
human/JJ
breast/NN
cancers/NNS
./.
====================
They/PRP
selected/VBN
the/DT
DEPs/NNS
between/IN
the/DT
serum/NN
samples/NNS
collected/JJ
from/IN
sensitive/JJ
and/CC
resistant/JJ
patients/NNS
to/TO
a/DT
combinatorial/JJ
chemotherapy/NN
using/VBG
doxorubicin/NN
and/CC
docetaxol/NN
and/CC
then/RB
further/RB
selected/VBN
the/DT
DEPs/NNS
with/IN
altered/JJ
expression/NN
of/IN
the/DT
corresponding/JJ
mRNAs/NNS
and/CC
proteins/NNS
in/IN
the/DT
breast/NN
tissue/NN
samples/NNS
./.
====================
During/IN
the/DT
validation/NN
of/IN
biomarker/NN
candidates/NNS
,/,
they/PRP
showed/VBD
that/IN
the/DT
DEPs/NNS
with/IN
the/DT
consistent/JJ
alteration/NN
in/IN
the/DT
tissues/NNS
showed/VBD
higher/JJR
accuracy/NN
in/IN
their/PRP$
validation/NN
using/VBG
western/NN
blotting/NN
for/IN
a/DT
validation/NN
cohort/NN
of/IN
independent/JJ
serum/NN
samples/NNS
./.
====================
Individual/JJ
patients/NNS
can/MD
show/VB
the/DT
variation/NN
in/IN
altered/JJ
molecules/NNS
of/IN
a/DT
cellular/JJ
pathway/NN
though/IN
the/DT
same/JJ
pathway/NN
is/VBZ
consistently/RB
perturbed/VBN
under/IN
disease/NN
conditions/NNS
./.
====================
Given/IN
the/DT
variation/NN
,/,
these/DT
molecules/NNS
can/MD
not/RB
be/VB
selected/VBN
as/IN
DEPs/NNS
using/VBG
the/DT
conventional/JJ
statistical/JJ
methods/NNS
,/,
thereby/RB
leading/VBG
to/TO
the/DT
failure/NN
to/TO
identify/VB
biomarkers/NNS
that/IN
reflect/VBP
the/DT
alteration/NN
of/IN
such/JJ
cellular/JJ
pathways/NNS
./.
====================
Thus/RB
,/,
it/PRP
has/VBZ
been/VBN
addressed/VBN
that/DT
cellular/JJ
pathways/NNS
can/MD
serve/VB
as/IN
a/DT
more/RBR
reliable/JJ
indicator/NN
of/IN
the/DT
altered/JJ
cellular/JJ
processes/NNS
under/IN
disease/NN
conditions/NNS
,/,
compared/VBN
to/TO
individual/JJ
molecules/NNS
[/(
58/CD
]/)
./.
====================
Different/JJ
types/NNS
of/IN
molecules/NNS
(/(
mRNA/proteins/NNS
,/,
microRNAs/NNS
,/,
DNA/NN
methylations/NNS
,/,
and/CC
metabolites/NNS
)/)
can/MD
represent/VB
distinct/JJ
layers/NNS
of/IN
cellular/JJ
networks/NNS
./.
====================
Thus/RB
,/,
a/DT
cellular/JJ
network/NN
can/MD
be/VB
modeled/VBN
in/IN
a/DT
multi-layered/JJ
network/NN
where/WRB
each/DT
layer/NN
can/MD
be/VB
delineated/VBN
by/IN
a/DT
distinct/JJ
type/NN
of/IN
the/DT
molecules/NNS
./.
====================
For/IN
example/NN
,/,
transcriptional/JJ
and/CC
microRNA/NN
regulatory/JJ
networks/NNS
are/VBP
defined/VBN
by/IN
interactions/NNS
of/IN
transcription/NN
factors/NNS
and/CC
microRNAs/NNS
,/,
respectively/RB
,/,
with/IN
their/PRP$
target/NN
mRNAs/NNS
./.
====================
Also/RB
,/,
cellular/JJ
signaling/NN
networks/NNS
are/VBP
defined/VBN
by/IN
protein-protein/JJ
interactions/NNS
(/(
kinase-substrate/NN
interactions/NNS
)/)
,/,
while/IN
DNA/NN
methylation/NN
networks/NNS
are/VBP
defined/VBN
by/IN
interactions/NNS
of/IN
methyltransferases/NNS
and/CC
demethylases/VBZ
with/IN
their/PRP$
target/NN
DNAs/NNS
and/CC
mRNAs/NNS
./.
====================
The/DT
integration/NN
of/IN
multiple/JJ
global/JJ
datasets/NNS
for/IN
different/JJ
types/NNS
of/IN
molecules/NNS
enables/VBZ
us/PRP
to/TO
decode/VB
the/DT
multi-layered/JJ
cellular/JJ
networks/NNS
associated/VBN
with/IN
the/DT
target/NN
disease/NN
./.
====================
A/DT
number/NN
of/IN
the/DT
tools/NNS
have/VBP
been/VBN
developed/VBN
to/TO
understand/VB
the/DT
subnetworks/NNS
(/(
network/NN
clusters/NNS
)/)
of/IN
the/DT
multi-layered/JJ
networks/NNS
whose/WP$
perturbations/NNS
are/VBP
collectively/RB
indicated/VBD
by/IN
different/JJ
types/NNS
of/IN
global/JJ
datasets/NNS
,/,
including/VBG
IPA/NN
(/(
QIAGEN/NN
Redwood/NN
City/NN
,/,
http/RB
:/:
//www.qiagen.com/ingenuity/NN
)/)
,/,
HotNet/NNP
[/(
62/CD
]/)
,/,
or/CC
SteinerNet/JJ
(/(
Table/JJ
1/CD
)/)
[/(
63/CD
]/)
./.
====================
Although/IN
these/DT
tools/NNS
can/MD
be/VB
applied/VBN
for/IN
integration/NN
of/IN
proteomic/JJ
data/NNS
with/IN
other/JJ
types/NNS
of/IN
global/JJ
data/NNS
,/,
they/PRP
have/VBP
been/VBN
used/VBN
mainly/RB
for/IN
integration/NN
of/IN
disparate/JJ
genomic/JJ
and/CC
transcriptomic/JJ
data/NNS
./.
====================
Recently/RB
,/,
Shi/NN
et/FW
al/JJ
./.
====================
[/(
64/CD
]/)
developed/VBD
NetGestalt/NN
that/DT
can/MD
be/VB
used/VBN
for/IN
integration/NN
of/IN
multi-dimensional/JJ
global/JJ
datasets/NNS
including/VBG
proteomic/JJ
data/NNS
./.
====================
For/IN
example/NN
,/,
using/VBG
NegGestalt/JJ
,/,
Zhu/NNP
et/FW
al/JJ
./.
====================
[/(
65/CD
]/)
identified/VBD
KRAS/JJ
and/CC
AKAP12/NN
subnetworks/NNS
that/DT
can/MD
play/VB
important/JJ
roles/NNS
in/IN
pathogenesis/NN
of/IN
colorectal/JJ
cancers/NNS
by/IN
integrating/VBG
proteomic/JJ
data/NNS
with/IN
mutation/NN
,/,
copy/NN
number/NN
variation/NN
,/,
DNA/NN
methylation/NN
,/,
and/CC
mRNA/NN
expression/NN
data/NNS
generated/VBD
from/IN
colon/NN
tissues/NNS
and/CC
cells/NNS
./.
====================
Finally/RB
,/,
the/DT
hub-like/JJ
molecules/NNS
in/IN
the/DT
subnetworks/NNS
are/VBP
selected/VBN
as/IN
key/JJ
indicators/NNS
of/IN
the/DT
alterations/NNS
of/IN
the/DT
disease-related/JJ
processes/NNS
associated/VBN
with/IN
the/DT
subnetworks/NNS
./.
====================
For/IN
example/NN
,/,
Iliopoulos/NN
et/FW
al/JJ
./.
====================
[/(
66/CD
]/)
identified/VBD
a/DT
set/NN
of/IN
the/DT
biomarker/NN
candidates/NNS
by/IN
performing/VBG
the/DT
network-based/JJ
integration/NN
of/IN
the/DT
proteome/NN
and/CC
microRNA/NN
expression/NN
data/NNS
./.
====================
Also/RB
,/,
The/DT
Cancer/NN
Genome/NN
Atlas/IN
(/(
TCGA/NN
)/)
research/NN
network/NN
identified/VBD
the/DT
notch/NN
signaling/NN
pathway/NN
as/IN
a/DT
key/JJ
molecule/NN
representing/VBG
the/DT
pathogenesis/NN
of/IN
ovarian/JJ
cancers/NNS
by/IN
integrating/VBG
somatic/JJ
mutation/NN
,/,
copy/NN
number/NN
variation/NN
,/,
and/CC
mRNA/NN
expression/NN
data/NNS
using/VBG
HotNet/JJ
analysis/NN
[/(
67/CD
]/)
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
summarized/VBD
a/DT
battery/JJ
of/IN
bioinformatics/NNS
analyses/NNS
for/IN
network-based/JJ
biomarker/NN
discovery/NN
using/VBG
LC-MS/MS/NN
data/NNS
./.
====================
These/DT
analyses/NNS
include/VBP
peptide/protein/NN
identification/NN
using/VBG
database/NN
search/VBP
engines/VBZ
,/,
peptide/protein/NN
quantification/NN
from/IN
MS/NN
or/CC
MS/MS/NN
data/NNS
,/,
identification/NN
of/IN
DEPs/NNS
using/VBG
statistical/JJ
methods/NNS
,/,
functional/JJ
enrichment/JJ
analysis/NN
of/IN
DEPs/NNS
using/VBG
diverse/JJ
enrichment/JJ
tools/NNS
,/,
and/CC
network/NN
modeling/VBG
and/CC
analysis/NN
of/IN
DEPs/NNS
,/,
as/IN
well/RB
as/IN
integrative/JJ
analysis/NN
of/IN
disparate/JJ
global/JJ
datasets/NNS
with/IN
the/DT
LC-MS/MS/NN
data/NNS
./.
====================
Peptide/NN
identification/NN
using/VBG
database/NN
search/VBP
has/VBZ
been/VBN
known/VBN
as/IN
a/DT
main/JJ
challenge/NN
./.
====================
Of/IN
the/DT
MS/MS/NN
spectra/NN
measured/VBN
,/,
about/RB
half/NN
of/IN
them/PRP
are/VBP
commonly/RB
mapped/VBD
to/TO
peptide/NN
sequences/NNS
./.
====================
The/DT
inclusion/NN
of/IN
PTMs/NNS
in/IN
database/NN
search/VBP
can/MD
map/VB
the/DT
unidentified/JJ
MS/MS/NN
spectra/NN
to/TO
peptide/NN
sequences/NNS
./.
====================
However/RB
,/,
the/DT
PTM/NN
inclusion/NN
exponentially/RB
increases/VBZ
the/DT
search/NN
time/NN
and/CC
thus/RB
it/PRP
would/MD
be/VB
practically/RB
impossible/JJ
to/TO
include/VB
the/DT
most/JJS
common/JJ
five/CD
PTMs/NNS
,/,
phosphorylation/NN
,/,
glycosylation/NN
,/,
ubiquitination/NN
,/,
methylation/NN
,/,
and/CC
acetylation/NN
in/IN
database/NN
search/VBP
./.
====================
Recently/RB
,/,
although/IN
several/JJ
search/NN
tools/NNS
,/,
such/JJ
as/IN
MODa/JJ
[/(
68/CD
]/)
,/,
with/IN
improved/JJ
search/VBP
speeds/VBZ
have/VBP
been/VBN
developed/VBN
,/,
there/EX
is/VBZ
still/RB
significant/JJ
needs/VBZ
for/IN
efficient/JJ
search/NN
tools/NNS
that/DT
can/MD
include/VB
the/DT
five/CD
common/JJ
PTMs/NNS
in/IN
the/DT
search/NN
./.
====================
Moreover/RB
,/,
protein/NN
quantification/NN
has/VBZ
been/VBN
also/RB
one/CD
of/IN
the/DT
challenges/NNS
in/IN
MS-based/JJ
proteomic/JJ
analysis/NN
./.
====================
Relative/JJ
protein/NN
abundances/VBZ
are/VBP
estimated/VBN
by/IN
combining/VBG
the/DT
ratios/NNS
of/IN
abundances/NNS
of/IN
the/DT
peptides/NNS
derived/VBN
from/IN
the/DT
protein/NN
./.
====================
The/DT
same/JJ
peptide/NN
sequences/NNS
can/MD
be/VB
derived/VBN
from/IN
multiple/JJ
proteins/NNS
due/JJ
to/TO
the/DT
redundancy/NN
in/IN
their/PRP$
sequences/NNS
,/,
which/WDT
can/MD
cause/VB
the/DT
discrepancy/NN
in/IN
the/DT
ratios/NNS
of/IN
the/DT
peptides/NNS
from/IN
the/DT
same/JJ
protein/NN
between/IN
control/NN
and/CC
patient/NN
samples/NNS
./.
====================
Also/RB
,/,
technical/JJ
and/CC
biological/JJ
variability/NN
can/MD
add/VB
the/DT
discrepancy/NN
to/TO
the/DT
peptide/NN
ratios/NNS
./.
====================
Because/IN
of/IN
these/DT
sources/NNS
of/IN
the/DT
discrepancy/NN
in/IN
the/DT
peptide/NN
ratios/NNS
,/,
it/PRP
has/VBZ
been/VBN
difficult/JJ
to/TO
estimate/VB
the/DT
relative/JJ
ratios/NNS
of/IN
protein/NN
abundances/VBZ
between/IN
control/NN
and/CC
patient/NN
samples/NNS
./.
====================
Recently/RB
,/,
although/IN
the/DT
optimization-based/VBN
quantification/NN
tools/NNS
,/,
such/JJ
as/IN
linear/JJ
programming/VBG
[/(
33/CD
]/)
,/,
have/VBP
been/VBN
developed/VBN
,/,
there/EX
have/VBP
been/VBN
significant/JJ
needs/VBZ
for/IN
the/DT
quantification/NN
methods/NNS
with/IN
improved/JJ
accuracy/NN
./.
====================
Due/IN
to/TO
the/DT
issue/NN
with/IN
protein/NN
quantification/NN
,/,
identification/NN
of/IN
DEPs/NNS
can/MD
be/VB
also/RB
erroneous/JJ
when/WRB
inaccurate/JJ
ratios/NNS
of/IN
protein/NN
abundances/VBZ
exist/VBP
./.
====================
Additional/JJ
criteria/NNS
,/,
such/JJ
as/IN
the/DT
number/NN
of/IN
patients/NNS
showing/VBG
fold-changes/VBZ
larger/JJR
than/IN
a/DT
cutoff/JJ
(/(
e.g./FW
,/,
1.5-fold/RB
)/)
,/,
are/VBP
used/VBN
to/TO
reduce/VB
the/DT
error/NN
(/(
false-positives/VBZ
)/)
in/IN
identification/NN
of/IN
DEPs/NNS
./.
====================
The/DT
error/JJ
in/IN
identification/NN
of/IN
DEPs/NNS
can/MD
further/RBR
propagate/VB
into/IN
functional/JJ
enrichment/JJ
analysis/NN
and/CC
network/NN
modeling/VBG
and/CC
analysis/NN
for/IN
the/DT
DEPs/NNS
./.
====================
Finally/RB
,/,
the/DT
integrative/JJ
analysis/NN
of/IN
disparate/JJ
global/JJ
datasets/NNS
suffers/NNS
from/IN
different/JJ
scales/NNS
of/IN
fold-changes/NNS
and/CC
the/DT
size/NN
of/IN
detected/VBN
molecules/NNS
in/IN
the/DT
different/JJ
types/NNS
of/IN
global/JJ
datasets/NNS
./.
====================
For/IN
example/NN
,/,
mRNA/NN
fold-changes/VBZ
between/IN
control/NN
and/CC
patient/NN
samples/NNS
can/MD
be/VB
relatively/RB
larger/JJR
than/IN
the/DT
fold-changes/NNS
of/IN
protein/NN
abundances/VBZ
,/,
which/WDT
may/MD
cause/VB
the/DT
bias/NNS
toward/IN
mRNA/NN
fold-changes/VBZ
during/IN
the/DT
integration/NN
of/IN
fold-changes/NNS
of/IN
mRNA/NN
and/CC
protein/NN
abundances/VBZ
./.
====================
Also/RB
,/,
differentially/RB
expressed/VBN
microRNAs/NNS
between/IN
control/NN
and/CC
patient/NN
samples/NNS
are/VBP
smaller/JJR
than/IN
the/DT
DEPs/NNS
or/CC
mRNAs/NNS
,/,
which/WDT
can/MD
lead/VB
to/TO
the/DT
bias/NNS
toward/IN
the/DT
DEPs/NNS
or/CC
mRNAs/NNS
during/IN
the/DT
integration/NN
./.
====================
Various/JJ
integration/NN
strategies/NNS
have/VBP
been/VBN
proposed/VBN
to/TO
reduce/VB
the/DT
intrinsic/JJ
bias/NNS
from/IN
the/DT
differences/NNS
in/IN
the/DT
size/NN
of/IN
disparate/JJ
global/JJ
datasets/NNS
./.
====================
For/IN
example/NN
,/,
in/IN
these/DT
methods/NNS
,/,
mRNA/NN
and/CC
protein/NN
abundance/NN
ratios/NNS
are/VBP
first/JJ
integrated/JJ
and/CC
the/DT
data/NNS
with/IN
small/JJ
sizes/NNS
are/VBP
separately/RB
integrated/VBN
to/TO
the/DT
outputs/NNS
from/IN
the/DT
initial/JJ
integration/NN
of/IN
mRNA/NN
and/CC
protein/NN
data/NNS
./.
====================
However/RB
,/,
regarding/VBG
the/DT
scale/NN
difference/NN
in/IN
fold-changes/NNS
,/,
there/EX
have/VBP
been/VBN
the/DT
needs/NNS
for/IN
the/DT
algorithms/NNS
that/DT
can/MD
effectively/RB
normalize/VBP
the/DT
different/JJ
scales/NNS
of/IN
fold-changes/NNS
in/IN
different/JJ
datasets/NNS
./.
====================
Basic/JJ
data/NNS
analysis/NN
pipeline/NN
for/IN
liquid/JJ
chromatography–tandem/JJ
mass/NN
spectrometry/NN
(/(
LC-MS/MS/NN
)/)
data/NNS
./.
====================
This/DT
pipeline/NN
includes/VBZ
peptide/protein/NN
identification/NN
,/,
peptide/protein/NN
quantification/NN
,/,
and/CC
identification/NN
of/IN
differentially/RB
expressed/VBN
proteins/NNS
(/(
DEPs/NNS
)/)
./.
====================
Each/DT
of/IN
bioinformatics/NNS
analyses/NNS
in/IN
the/DT
pipeline/NN
is/VBZ
schematically/RB
shown/VBN
together/RB
with/IN
the/DT
concepts/NNS
and/CC
the/DT
tools/NNS
./.
====================
PSMs/NNS
,/,
peptide-spectrum/NN
matches/NNS
;/:
FDRs/NNS
,/,
false/VBP
discovery/NN
rates/NNS
;/:
iCAT/RB
,/,
isotope-coded/VBD
affinity/NN
tag/NN
;/:
iTRAQ/RB
,/,
isobaric/JJ
tag/NN
for/IN
relative/JJ
and/CC
absolute/JJ
quantitation/NN
;/:
TMT/NN
,/,
tandem/JJ
mass/NN
tags/NNS
./.
====================
Schematics/NNS
for/IN
functional/JJ
enrichment/JJ
and/CC
network/NN
analyses/NNS
of/IN
differentially/RB
expressed/VBN
proteins/NNS
(/(
DEPs/NNS
)/)
./.
====================
Three/CD
types/NNS
of/IN
functional/JJ
enrichment/JJ
analyses/NNS
are/VBP
shown/VBN
./.
====================
The/DT
output/JJ
from/IN
gene/NN
set/NN
enrichment/JJ
analysis/NN
(/(
GSEA/NN
)/)
is/VBZ
displayed/VBN
as/IN
an/DT
example/NN
./.
====================
Also/RB
,/,
an/DT
example/NN
of/IN
network/NN
model/NN
is/VBZ
shown/VBN
,/,
which/WDT
includes/VBZ
functional/JJ
modules/NNS
1-3/CD
(/(
cell/NN
adhesion/NN
,/,
vasculature/NN
development/NN
,/,
and/CC
cell/NN
death/NN
,/,
respectively/RB
)/)
./.
====================
Node/RB
colors/NNS
in/IN
the/DT
network/NN
model/NN
represent/JJ
up-/RB
(/(
red/JJ
)/)
and/CC
down-regulation/NN
(/(
green/CD
)/)
,/,
the/DT
color/JJ
gradient/NN
denotes/VBZ
log2-fold-changes/VBZ
of/IN
the/DT
proteins/NNS
,/,
and/CC
gray/NN
lines/NNS
represent/VBP
the/DT
connections/NNS
between/IN
the/DT
nodes/NNS
./.
====================
GOBPs/NNS
,/,
gene/NN
ontology/NN
biological/JJ
processes/NNS
;/:
KEGG/NN
,/,
Kyoto/NN
Encyclopedia/NN
of/IN
Genes/NNS
and/CC
Genomes/NNS
;/:
TGF/NN
,/,
tumor/NN
growth/NN
factor/NN
./.
====================
Integrative/JJ
analysis/NN
of/IN
proteomic/JJ
data/NNS
with/IN
other/JJ
types/NNS
of/IN
global/JJ
data/NNS
./.
====================
The/DT
concepts/NNS
for/IN
molecular/JJ
level/NN
(/(
A/NN
)/)
and/CC
network/NN
based/VBN
integration/NN
(/(
B/NN
)/)
are/VBP
shown/VBN
./.
====================
In/IN
the/DT
top/NN
panel/NN
,/,
two/CD
example/JJ
cases/NNS
(/(
one/CD
for/IN
tissue/NN
data/NNS
and/CC
the/DT
other/JJ
for/IN
serum/NN
data/NNS
)/)
are/VBP
illustrated/VBN
,/,
and/CC
also/RB
one/CD
example/NN
case/NN
for/IN
integrative/JJ
analysis/NN
of/IN
three/CD
types/NNS
of/IN
global/JJ
datasets/NNS
(/(
proteomic/JJ
,/,
mRNA/NN
expression/NN
,/,
and/CC
DNA/histone/NN
methylation/NN
data/NNS
)/)
is/VBZ
shown/VBN
./.
====================
In/IN
the/DT
bottom/CC
panel/NN
,/,
network/NN
based/VBN
integration/NN
of/IN
four/CD
types/NNS
of/IN
global/JJ
data/NNS
using/VBG
differentially/RB
expressed/VBN
molecules/NNS
from/IN
them/PRP
are/VBP
schematically/RB
displayed/VBD
./.
====================
DEPs/NNS
,/,
differentially/RB
expressed/VBN
proteins/NNS
;/:
IGF/NN
,/,
insulin-like/JJ
growth/NN
factor/NN
;/:
LC-MS/MS/NN
,/,
liquid/JJ
chromatography–tandem/JJ
mass/NN
spectrometry/NN
./.
====================
Resources/NNS
for/IN
network-based/JJ
protein/NN
biomarker/NN
discovery/NN
====================
